R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 34, 2009, Pages 14622-14627

  Tong, Youren ^a   Pisani, Antonio ^b   Martella, Giuseppina ^b   Karouani, Maha ^c   Yamaguchi, Hiroo ^a   Pothos, Emmanuel N ^c   Shen, Jie ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; Dopamine D2 receptor; Knockin; Parkinson's disease; Quinpirole

Indexed keywords

AMPHETAMINE; CATECHOLAMINE; DOPAMINE; LEUCINE RICH REPEAT KINASE 2; QUINPIROLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL CULTURE; CHROMAFFIN CELL; DOPAMINERGIC NERVE CELL; ELECTROPHYSIOLOGY; GENE; GENE EXPRESSION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LEUCINE RICH REPEAT KINASE 2 GENE; LOCOMOTION; MISSENSE MUTATION; MOUSE; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STEADY STATE; STRIATE CORTEX;

ACTION POTENTIALS; ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN; CATECHOLAMINES; CELLS, CULTURED; CHROMAFFIN CELLS; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; MOTOR ACTIVITY; MUTATION; NEURONS; PROTEIN-SERINE-THREONINE KINASES; QUINPIROLE; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

MUS;

EID: 70149124508     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906334106     Document Type: Article

References (45)

1. Paisan-Ruiz C, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600. (Pubitemid 39531224)
2. Zimprich A, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607. (Pubitemid 39531225)
3. Mata IF, et al. (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6:171-177. (Pubitemid 41720888)
4. Skipper L, et al. (2005) Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Hum Mol Genet 14:3549-3556. (Pubitemid 41754656)
5. Berg D, et al. (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128:3000-3011.
6. Taylor JP, Mata IF, Farrer MJ (2006) LRRK2: A common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med 12:76-82.
7. Di Fonzo A, et al. (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14:322-331.
8. Funayama M, et al. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57:918-921. (Pubitemid 40798631)
9. West AB, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:16842-16847. (Pubitemid 41688864)
10. Smith WW, et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233.
11. Greggio E, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23:329-341. (Pubitemid 44097032)
12. West AB, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16:223-232.
13. Ito G, et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46:1380-1388. (Pubitemid 46208485)
14. Smith WW, et al. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 102:18676-18681.
15. MacLeod D, et al. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52:587-593. (Pubitemid 44781171)
16. Biskup S, et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60:557-569. (Pubitemid 44871798)
17. Shin N, et al. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314:2055-2065.
18. Lee SB, Kim W, Lee S, Chung J (2007) Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun 358:534-539. (Pubitemid 46755736)
19. Liu Z, et al. (2008) A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci USA 105:2693-2698.
20. Zabetian CP, et al. (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65:741-744. (Pubitemid 41285855)
21. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272.
22. Meloni EG, Davis M (2000) Synergistic enhancement of the acoustic startle reflex by dopamine D1 and 5-HT1A agonists and corresponding changes in c-Fos expression in the dorsal raphe of rats. Psychopharmacology 151:359-367.
23. Robertson SD, Matthies HJ, Galli A (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39:73-80.
24. Garcia AG, Garcia-De-Diego AM, Gandia L, Borges R, Garcia-Sancho J (2006) Calcium Signaling and Exocytosis in Adrenal Chromaffin Cells. Physiol Rev 86:1093-1131. (Pubitemid 44523705)
25. Neher E (2006) A comparison between exocytic control mechanisms in adrenal chromaffin cells and a glutamatergic synapse. Pflugers Arch 453:261-268.
26. Goldberg MS, et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45:489-496.
27. Starke K, Gothert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864-989. (Pubitemid 19184852)
28. Johnson SW, Seutin V, North RA (1992) Burst firing in dopamine neurons induced by N-methyl-D-aspartate: Role of electrogenic sodium pump. Science 258:665-667.
29. Lacey MG, Mercuri NB, North RA (1987) Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J Physiol 392:397-416.
30. Mercuri NB, Bonci A, Calabresi P, Stefani A, Bernardi G (1995) Properties of the hyperpolarization-activated cation current Ih in rat midbrain dopaminergic neurons. Eur J Neurosci 7:462-469.
31. Mercuri NB, Calabresi P, Bernardi G (1990) Responses of rat substantia nigra compacta neurones to L-DOPA. Br J Pharmacol 100:257-260. (Pubitemid 20170639)
32. Mercuri NB, et al. (1997) Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 79:323-327.
33. Goldberg MS, et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278:43628-43635.
34. Yamaguchi H, Shen J (2007) Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice. Mol Neurodegener 2:10. (Pubitemid 46919092)
35. Kitada T, et al. (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci USA 104:11441-11446. (Pubitemid 47175159)
36. Kantor L, et al. (2001) Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J Pharmacol Exp Ther 297:1016-1024. (Pubitemid 32472499)
37. Gnegy ME, et al. (2004) Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol Pharmacol 66:137-143.
38. Usiello A, et al. (2000) Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199-203. (Pubitemid 30839420)
39. Centonze D, et al. (2002) Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology 27:723-726. (Pubitemid 35335890)
40. Jenner P (2003) Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 16:S3-S7. (Pubitemid 38328107)
41. Noble EP (2000) The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics 1:309-333.
42. Whone AL, et al. (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54:93-101. (Pubitemid 36764985)
43. Kitamura Y, Taniguchi T, Shimohama S, Akaike A, Nomura Y (2003) Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem Res 28:1035-1040. (Pubitemid 36576200)
44. Li Y, et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12:826-828.
45. Pothos EN, et al. (2002) Stimulation-dependent regulation of the pH, volume and quantal size of bovine and rodent secretory vesicles. J Physiol 542:453-476.